Isodiol International Inc. continues to position itself as the go-to partner to supply cannabidiol (CBD) isolate of the highest quality. The company just signed a letter of intent to supply CBD isolate to Sundial Growers Inc.
Isodiol will supply 99.5% pure CBD isolate to Sundial through its wholly owned subsidiary called BSPG Laboratories in the United Kingdom (UK). BSPG recently received government approval from UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). The approval gives Isodiol the ability to manufacture and export CBD to global markets from the UK.
The approval sets Isodiol apart from all other CBD companies worldwide. It positions Isodiol as a reliable supplier that can serve the growing demand for CBD drug development. The validation will push research, clinical studies, and clinical trials to create innovative CBD solutions.
Sundial operates a 31,000 square foot production facility in Rocky View, Alberta. It has two more production facilities that are in development. Sundial combines traditional farming practices with innovative horticultural techniques to grow a select range of cannabis strains.
The agreement is a step toward its goals to expand operations. It aims to produce over 100 million grams of dry cannabis and the ability to process over 32 million grams of cannabis extracts.
The Isodiol team is also excited to join hands with Sundial to help them produce quality products that customers can trust.
According to Sundial CEO Tosten Kuenzlen, the demand for CBD products in Canada will remain strong. The deal gives the company the opportunity to formulate new products with Isodiol’s pharmaceutical and nutraceutical grade CBD isolate.
Under the terms of the agreement, Isodiol will import CBD into Canada through a licensed dealer approved by Health Canada. Sundial will also check all imported products to ensure they comply with Canadian standards.
Sundial and Isodiol intend to execute a definitive supply agreement, which will be subject to regulatory approvals. These include permits and approvals from applicable exchanges and government authorities in the UK and Canada.
About Isodiol International Inc.
Isodiol is a market leader in the development of pharmaceutical-grade phytochemical compounds and CBD consumer products. It is one of the pioneers in the commercialization of 99%+ pure cannabinoids, microencapsulation, and nanotechnology.
The company manufactures the highest-quality consumable and topical products for skin care and pain management.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and the expansion of its phytoceutical portfolio. Besides this, the company plans to aggressively expand into international markets like Latin America, Asia, and Euro